摘要
目的:评价内皮素受体拮抗药(ETRA)预防和治疗脑血管痉挛的效果。方法:对随机双盲安慰剂对照临床试验进行系统评价和荟萃分析。结果:3个研究符合纳入标准,861例完成了试验观察。ETRA组脑血管痉挛、迟发性缺血性神经功能缺损和迟发性神经功能缺损,以及新发脑梗死的风险分别为安慰剂组的58%(RR=0.58,95%CI:0.48～0.71,P<0.00001),76%(RR=0.76,95%CI:0.60～0.96,P=0.02)和47%(RR=0.47,95%CI:0.28～0.78,P=0.003);2组患者临床转归没有差异(死亡:RR=1.08,95%CI:0.72～1.63,P=0.71;死亡、植物状态和严重残疾:RR=0.91,95%CI:0.72～1.13,P=0.39)。结论:ETRA极大降低了蛛网膜下腔出血患者脑血管痉挛的风险,但是,目前尚无证据表明ETRA可以改善患者的临床转归。
OBJECTIVE: To investigate the preventive and therapeutic efficacy of endothelin receptor antagonist (ETRA) on cerebral vasospasm. METHODS: The therapeutic efficacy of ETRA in the treatment of cerebral vasospasm was evaluated through system evaluation and Meta-analysis of clinical randomized double-blind controlled trials. RESULTS: 3 studies were enrolled and observation test was completed in 861 patients. The risk of cerebral vasospasm,delayed ischemic neurological deficit(DIND)& delayed neurological defici...
出处
《中国药房》
CAS
CSCD
北大核心
2011年第6期525-529,共5页
China Pharmacy
关键词
蛛网膜下腔出血
脑血管痉挛
内皮素受体拮抗药
临床转归
不良反应
荟萃分析
Subarachnoid hemorrhage
Cerebral vasospasm
Endothelin receptor antagonist
Clinical prognosis
Adverse reaction
Meta-analysis
